Open AccessA Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial
Author(s) -
Tadao Akizawa,
Masaomi Nangaku,
Takuhiro Yamaguchi,
Masanobu Arai,
Ryosuke Koretomo,
Atsushi Matsui,
Hideki Hirakata
Publication year - 2019
Publication title -
american journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 85
eISSN - 1421-9670
pISSN - 0250-8095
DOI - 10.1159/000496929
Subject(s) - medicine , kidney disease , anemia , placebo , hemoglobin , dialysis , randomized controlled trial , erythropoiesis , gastroenterology , erythropoietin , hepcidin , ferritin , urology , surgery , pathology , alternative medicine
Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that mimics adaptive responses to hypoxic conditions and may provide a new therapeutic approach for managing anemia in patients with chronic kidney disease (CKD). We evaluated the efficacy, safety, and maintenance dose of enarodustat in anemic patients with CKD not on dialysis.